Clinical Trials Logo

Infection clinical trials

View clinical trials related to Infection.

Filter by:

NCT ID: NCT04915586 Completed - Loculated Empyema Clinical Trials

Short Duration High Intensity Intrapleural Alteplase With Pulmozyme in Pleural Infection Management

Start date: December 30, 2019
Phase: N/A
Study type: Interventional

The aim of this study was to assess the efficacy of the modified regimen short duration intrapleural 16mg alteplase (Actilyse, Boehringer Ingelheim) with 5mg DNase (Pulmozyme Hoffmann-La Roche Ltd) in patients with pleural infection.

NCT ID: NCT04912180 Terminated - Influenza Clinical Trials

Apple Respiratory Study

ARS
Start date: April 6, 2021
Phase:
Study type: Observational

The Apple Respiratory Study, a collaboration between researchers at Apple Inc. (the "Study Sponsor" or "Sponsor") and the Seattle Flu Study team at the University of Washington (UW) (the "UW Study Team"), is a prospective, longitudinal cohort, low risk Study to collect certain data from Apple Watch and iPhone to determine whether such data can detect physiologic and non-physiologic changes in individuals associated with respiratory illnesses due to influenza, SARS-CoV-2 and other respiratory pathogens (the "Study").

NCT ID: NCT04910698 Completed - Clinical trials for Acute Myeloid Leukemia

Efficacy of Antibiotic Short Course for Bloodstream Infections in Acute Myeloid Leukemia Patients With Febrile Neutropenia

Start date: January 1, 2020
Phase:
Study type: Observational

There is no specific recommendation about antimicrobial treatment length for documented infections in chemotherapy induced febrile neutropenia. The aim of this study was to compare long versus short antibiotic course for bloodstream infection treatment in acute myeloid leukemia patients during febrile neutropenia. This monocentric retrospective comparative study included all consecutive bloodstream infection episodes among acute myeloid leukemia patients with febrile neutropenia for 3 years (2017-2019). Episodes were classified regarding the length of antibiotic treatment, considered as short course if the treatment lasted ≤7 days, except for nonfermenting bacteria and Staphylococcus aureus or lugdunensis for which the threshold was ≤10 days and ≤14 days, respectively. The primary outcome was the number of bloodstream infection relapses in both groups within 30 days of antibiotic discontinuation.

NCT ID: NCT04906304 Completed - Clinical trials for Cytomegalovirus Infections

Comparison of Safety and Efficacy of de Novo Everolimus

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

Nowadays, de novo everolimus regimen in renal transplant patients is considered for reduction of cyclosporine dose and it is mentioned that this regimen not only has similar safety and efficacy, but also could prevent Cytomegalovirus (CMV )infections. So, the aim of this study was comparison of safety and efficacy of de novo everolimus plus low dose of cyclosporine with standard dose of cyclosporine plus cellcept on CMV virus infections prevention in renal transplant patients.

NCT ID: NCT04903886 Not yet recruiting - Bacteremia Clinical Trials

Intensive Care Unit Acquired Infections in Patients Colonized With Extended Spectrum Enterobacteriaceae

BMREA
Start date: June 1, 2021
Phase:
Study type: Observational

Worldwide emergence of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) had become a major problem in ICU, with at least 10% of incidence at the admission in Europe. A systematic rectal swab is used in 70% of French ICU to detect intestinal ESBL-E carriage The relationship between intestinal carriage and ICU-acquired infection is not perfectly known. The investigators conducted a five years study monocentric retrospective observational cohort in patients with presence of extended-spectrum β-lactamase-producing Enterobacteriaceae in systematic rectal swabs to investigate which type of infections and which bacteria are involved. The investigators also collect data about antibiotherapy used to treat these infections.

NCT ID: NCT04903847 Recruiting - Obesity Clinical Trials

Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil

AVERTAS-2
Start date: February 2, 2021
Phase: Phase 4
Study type: Interventional

Randomized controlled parallel open-label study in persons living with HIV. The aim is to study weight changes in patients switching from a dolutegravir and tenofovir disoproxil containing regimen to either a dolutegravir or tenofovir disoproxil free regimen.

NCT ID: NCT04898452 Recruiting - Infection Clinical Trials

Intravenous Antibiotic Treatment at Home

Hosp@Home
Start date: July 2, 2020
Phase:
Study type: Observational

The purpose of the study is to develop and evaluate a new model for across services interaction with the use of welfare technology and telemedicine. The model includes innovative and new routines for the exchange of patient information, quality systems and procedures between the municipality and the hospital. This model will first be tested for use in intravenous antibiotic therapy. The results of the study will be used to further develop the service. In the larger context, it is desirable to provide knowledge that is transferable to other diagnostic groups, treatment methods and geographical areas.

NCT ID: NCT04895774 Not yet recruiting - Clinical trials for Microbial Colonization

Ex Vivo Study of the Mechanism of Action of Active Ingredients on the Intestinal Microbiota

Start date: September 2021
Phase:
Study type: Observational

To design and understand the mechanism of action of different combinations of nutraceuticals coupling bacteria, fibers and polyphenols, which can act on the 4 pillars simultaneously via an innovative ex-vivo model approach coupled with functional and quantitative metagenomics.

NCT ID: NCT04895657 Completed - Clinical trials for Gram-Negative Infections

Extended-infusion of Piperacillin-Tazobactam Versus Intermittent Infusion

Start date: July 27, 2018
Phase: Phase 4
Study type: Interventional

Continuous-infusion of piperacillin/tazobactam over 4 hrs instead of 30-minute intermittent dosage regimen has shown observable outcomes. Our objective is to assess whether continuous infusion of piperacillin/tazobactam is superior in terms of efficacy, safety and cost to the intermittent regimen to treat suspected or proved infections due to gram negative bacteria. The setting is Critical Care Medicine Department at Cairo University Hospitals. Methods A prospective randomized comparative study.

NCT ID: NCT04893694 Completed - SARS-CoV2 Infection Clinical Trials

the Prevalence of Oral Manifestation in Patients With SARS-CoV2 Infection

Start date: May 20, 2021
Phase:
Study type: Observational

The SARS-Cov2 virus was identified in china at the end of 2019 and spread worldwide causing a global pandemic. Current research showed that SARS-Cov2 virus invades human cells via the receptor angiotensin-converting enzyme 2 (ACE2) through scRNA-seq data analyses. The study identified the organs that are at risk and are vulnerable to SARS-CoV-2 infection. Therefore, cells with ACE2 receptor distribution may become host cells for the virus and cause inflammatory response in related organs and tissues, such as the tongue mucosa and salivary glands. These results suggest that oral mucosa could be a target of SARS-CoV-2 infection